BGB324    ​ -  CML  - Chronic myeloid leukemia

BGB324 has potential application as a  novel treatment for Chronic Myeloid  Leukemia (CML), was  presented in  a poster at the Annual Meeting of the American Society of Hematology (ASH 2013). BGB324 was effective in treating animals infected with CML cells expressing the T315I  mutation of ABL.

                                        See also Mutation T315I​